Breast Cancer Treatment in Europe

Publication
Article
OncologyONCOLOGY Vol 11 No 12
Volume 11
Issue 12

Screening for breast cancer has been shown in several European randomized trials and case-control studies to reduce breast cancer mortality. These studies highlight the importance of quality assurance in the whole screening process. The Europe

Screening for breast cancer has been shown in several European randomized trials and case-control studies to reduce breast cancer mortality. These studies highlight the importance of quality assurance in the whole screening process. The Europe Against Cancer Program (EAC) is funding the European pilot breast cancer screening network, in which quality improvement based on the European quality assurance guidelines is the central target.

“Major advances are taking place in the field of breast cancer, particularly in the understanding of which women are at high risk,” says Professor Bruce Ponder of the Department of Clinical Oncology, Addenbrooke’s Hospital, Cambridge, United Kingdom. “But, as yet, there are no prognostic markers to tell us that screening-detected or genetic breast cancer should be treated differently from clinically detected breast cancer.”

“Testing in the population at large, or of women with only one or two affected relatives is, in general, premature. We also know that some uncommon genes predispose some people to cancer. These provide the basis for DNA based tests for cancer susceptibility, but the ethical issues that surround these tests are exceedingly complex,” he added.

“We know already that more than 10% of cases of breast cancer are attributable to mutations in susceptible genes, such as BRCA1 and 2. The challenge now for medical oncologists is to integrate traditional systemic breast cancer therapies, such as hormone and chemotherapy, with genetic approaches.”

For the present, however, Dr. Marie Overgaard, from the Aarhus University Hospital in Denmark, has shown how existing therapies can be used to the best effect. Her study demonstrates that survival in high-risk patients with breast cancer is significantly improved by an optimal combination of surgery and irradiation plus adjuvant systemic therapy, when compared with adjuvant therapy alone (see below).

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content